Univar Announces Distribution Agreement with Swati Spentose for Lidocaine Products
News Oct 23, 2013
Univar is announcing the partnership at CPhl Worldwide Oct. 22 – 24 in Frankfurt, Germany, where it will be showcasing its pharmaceutical portfolio and technical expertise.
The agreement with Swati Spentose Pvt. Ltd. includes distribution in the United States and Puerto Rico for both Lidocaine Base and Lidocaine HCl. The products are used in a variety of anaesthetic and antiarrhythmic applications in the form of topical, oral, transdermal and injectable products.
“We are very excited to begin this relationship with Swati Spentose,” said Tom Nist, Univar USA Director of Pharmaceutical Ingredients. “The combined manufacturing expertise from Swati Spentose and Univar’s marketing and sales capabilities offers customers greater access to these active pharmaceutical ingredients (API). The Lidocaine Base and Lidocaine HCl are excellent additions to Univar’s API portfolio.”
Univar’s offering to pharmaceutical manufacturers extends beyond traditional technical and formulation support. It includes detailed insight into the industry’s market trends and complex regulatory demands, including stringent quality control and services such as change control management.
“As part of our ongoing commitment to world class manufacturing, we are focused on partnering with companies across the value chain to provide the most comprehensive service to our customers,” said Swati Jajodia, CEO, Swati Spentose Pvt. Ltd. “Univar’s extensive distribution network and commitment to safety, makes it an excellent partner to help us reach more customers with our lidocaine products.”
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018